AbbVie's Botox, dermal fillers face slowdown jitters
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
AbbVie (ABBV) Falls Following Q3 Release - Softness in US Sales Likely to 'Raise Concerns'
October 28, 2022 9:53 AM EDTAbbVie (NYSE: ABBV) shares are down more than 5% in early Friday trading after the company reported third-quarter earnings before the open, missing revenue expectations.
The company reported earnings of $3.66 per share, $0.08 better than the analyst estimate of $3.58, while revenue for the quarter came in at $14.81 billion versus the consensus estimate of $14.93 billion.
Following the report, Mizuho Securities analyst Uy Ear told investors in a note... More
